The GLP-1 class changed the weight-loss conversation permanently. But the muscle-loss problem embedded in every GLP-1 protocol has created demand for the next class — one that can match the fat loss while preserving the muscle. That class is amylin analogs, and the pipeline is moving fast enough that the first candidates could reach the market before the muscle-preservation question in current GLP-1 trials is even fully answered.
⚡ Key Takeaway
Amylin analogs represent the next generation of weight-loss drugs with a potentially better muscle-preservation profile than GLP-1 agonists alone. CagriSema (cagrilintide + semaglutide) showed 22.7% weight loss in Phase 2. Petrelintide, AZD6234 (APRICUS), and amycretin are in various stages of development.
What Amylin Is and Why It Matters
Amylin is a hormone co-secreted with insulin from pancreatic beta cells after meals. It works through several mechanisms: slowing gastric emptying (like GLP-1), promoting satiety through direct action on the brain’s appetite centers (like GLP-1 but through different receptors), and — critically — modulating energy expenditure in ways that may favor fat over lean tissue catabolism.
The amylin pathway is distinct from GLP-1. Where GLP-1 drugs primarily create a caloric deficit through appetite suppression, amylin analogs appear to additionally influence the body’s metabolic partitioning — how it decides what to burn when in deficit. Early data suggests amylin receptor activation favors adipose tissue catabolism over muscle protein breakdown, which is exactly the pharmacologic profile the performance community has been waiting for.
The Key Players
CagriSema (Novo Nordisk)
CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide (GLP-1 agonist) in a single once-weekly injection. The Phase 2 data showed 22.7% weight loss at 68 weeks, exceeding semaglutide alone. The Phase 3 REDEFINE program is the most advanced in this class, and Novo is running it as a direct challenge to tirzepatide — the first head-to-head trial between an amylin/GLP-1 combination and a GIP/GLP-1 dual agonist. That head-to-head data will be the most important trial readout of 2026-2027 for the physique-focused community.
Petrelintide (Novo Nordisk)
Petrelintide is a standalone amylin analog being developed as both a monotherapy and a combination partner. Phase 2 data showed meaningful weight loss with a body-composition profile that generated significant interest: the lean-mass preservation ratio appeared notably better than what GLP-1 monotherapy typically achieves. The caveat is sample size — Phase 2 trials are small, and the composition data needs Phase 3 confirmation.
AZD6234 / APRICUS (AstraZeneca)
AstraZeneca’s amylin receptor agonist is earlier in development but represents the broadening of the class beyond Novo Nordisk’s dominance. Multiple companies pursuing amylin-pathway drugs validates the mechanism and increases the probability that at least one muscle-sparing weight-loss drug reaches market.
Amycretin (Novo Nordisk)
Amycretin is a dual amylin/GLP-1 receptor agonist in a single molecule — similar to how tirzepatide is a dual GIP/GLP-1 agonist. Phase 1 data showed weight loss exceeding what semaglutide achieves at equivalent timepoints. The single-molecule approach simplifies dosing compared to CagriSema’s two-compound combination.
The Muscle-Preservation Hypothesis
The amylin class’s potential advantage for muscle preservation rests on two proposed mechanisms. First, amylin receptor activation appears to influence energy substrate selection at the cellular level, shifting the deficit’s metabolic cost toward fat oxidation rather than protein catabolism. Second, the satiety profile of amylin analogs may be qualitatively different from GLP-1s — reducing appetite without the same degree of protein-specific appetite suppression that makes eating adequate protein so difficult on semaglutide.
Both mechanisms are biologically plausible and supported by early data, but neither is conclusively proven in large human trials. The Phase 3 composition data from REDEFINE will be the first definitive answer, and it will reshape the entire weight-loss drug market depending on the outcome.
What This Means for Your Protocol Now
If you are currently on a GLP-1 drug, the amylin class is not yet available as an alternative. CagriSema’s timeline depends on Phase 3 results and regulatory review — realistically 2027-2028 for market access. In the meantime, the muscle-preservation strategies that work for current GLP-1s (resistance training, high protein, creatine, potentially lower doses) remain the best available countermeasures.
If you are considering starting a GLP-1 protocol and muscle preservation is a priority, the emerging amylin data is relevant to your timing decision. The drug that arrives in 18-24 months may offer a better muscle-preservation profile than what is available today. Whether that timeline aligns with your goals is a personal calculation.